Our study demonstrates that absence of Nox4 results in similar renoprotection as that observed in the PKC dKO mice suggesting that a pharmacological approach to reduce Nox4 expression would be a suitable therapeutic strategy to consider as a way of inhibiting multiple PKC isoforms and thus acting as a novel effective renoprotective approach in diabetes. Here, NOX4 is linked to diabetes mellitus.